Immunovaccine (OTCQX:IMMVF; TSX:IMV) expects to report three clinical milestones for its killer T cell activation vaccine platform, DepoVax, in ovarian and HPV cancers in the next 12 months.
“Our DepoVax platform has the potential to revolutionize immunotherapy in multiple areas, such as oncology and infectious diseases,” CEO, Frederic Ors, says in an interview with BioTuesdays.com.
Last week, ImmunoVaccine reported positive top-line results from its Phase 1 trial evaluating the safety and immunogenicity of DPX-RSV, its DepoVax-based, small B cell epitope peptide vaccine candidate for respiratory syncytial virus (RSV).
As a partner and biotechnology analyst with William Blair & Co., Y. Katherine Xu was recognized in 2010 by the Financial Times/StarMine “World’s Top Analysts” listing, ranking No. 7 overall for stock-picking in the U.S., and No. 2 for stock-picking in biotech in 2011. She also received the No. 2 ranking in The Wall Street Journal’s “Best on the Street” listing in 2011. Prior to joining William Blair in 2011, Ms. Xu was a SVP and senior biotech analyst at Wedbush Securities; VP and senior biotech analyst at Credit Suisse; and a senior biotech analyst at Pacific Growth Equities. Before her move into equity research, Ms. Xu worked in investment banking for two years. In this interview with BioTuesdays.com, Ms. Xu discusses her industry-leading research report entitled, Hepatitis B: The Next Frontier, and some of her best investment ideas in the Hep B space.
Mesoblast (NASDAQ:MESO; ASX:MSB) has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells (MLCs), to establish a broad portfolio of late-stage product candidates.
“This technology has the potential to target advanced stages of diseases, with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions,” CEO and managing director, Dr. Silviu Itescu, says in an interview with BioTuesdays.com.
Dr. Itescu explains Mesoblast’s MLCs are rare cells and central to blood vessel maintenance, repair and regeneration, largely via secretion of growth factors, which act on neighboring endothelial cells to promote blood vessel regeneration and function.
As it transitions from a discovery and technology platform-focused organization to a clinical stage biotech company, Critical Outcome Technologies (OTCQB:COTQF; TSX-V:COT) is approaching a critical inflection point by mid-2017 with its lead program, COTI-2, in in gynaecological cancers.
COTI-2 is currently being evaluated in a Phase 1 clinical study at two premier cancer centers in the U.S.
“We’ve assembled an impressive amount of supportive preclinical data in the past for COTI-2, and are excited to be evaluating in the clinic this potentially significant therapeutic option for women suffering from debilitating gynecological cancers, such as ovarian cancer,” Alison Silva, president, says in an interview with BioTuesdays.com.
In the more than 30 months since its startup, Knight Therapeutics (TSX:GUD) has shown an uncanny knack for raising equity at increasing valuations, building a portfolio of some 20 innovative products for its pipeline, expanding internationally and investing in life science funds to gain access to new pharmaceuticals.
“Over the next 30 months, we want to get real and demonstrate that we are good at commercializing and selling innovative pharmaceuticals that touch people's lives,” CEO, Jonathan Ross Goodman, says in an interview with BioTuesdays.com.
“In the highly competitive Canadian licensing landscape, we have been more creative and are adding more horsepower to our licensing capabilities,” he adds, noting that all of Knight’s products are sourced through partnerships and acquisitions.
Mateon Therapeutics (NASDAQ:MATN) is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal tumor blood vessels, which supply nutrients to cancer cells, with an initial clinical focus on platinum-resistant ovarian cancer and acute myeloid leukemia.
“VDAs have been around for a long time but we’re taking them in a new direction: in combination with anti-angiogenic (AA) therapies,” president and CEO, Dr. William Schwieterman, says in an interview with BioTuesdays.com.
Stifel initiated coverage of Xenon Pharmaceuticals (NASDAQ:XENE) with a “buy” rating and $18 price target. The stock closed at $8.35 on Oct. 20.
Analyst Stephen Willey writes that Xenon has successfully leveraged its Extreme Genetics drug discovery platform, which identifies single-gene defects responsible for severe human phenotypes, into a maturing pipeline of both partnered and wholly-owned product candidates on the precipice of achieving proof-of-concept inflection points.
Titan Pharmaceuticals’ (NASDAQ: TTNP) Probuphine implant has been recognized as one of the "12 Most Important Innovations of the Year" in the health category in Popular Science's annual Best of What's New issue.
Probuphine, a subdermal implant developed using Titan's proprietary ProNeura technology, was approved by the FDA in May, becoming the first commercially available long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or less a day of oral buprenorphine.
Dipexium Pharmaceuticals (NASDAQ:DPRX) updated the status of results from two pivotal Phase 3 clinical trials - OneStep-1 and OneStep-2- of its topical antimicrobial peptide, Locilex, for the treatment of diabetic foot ulcers.
Data tables and listings from both of these trials are currently being produced and evaluated by the company's scientific advisors according to a pre-specified data review procedure.
3D Signatures (TSX-V:DXD) announced its participation in a major clinical trial for prostate cancer diagnosis and management, known as PRECISE, marking the company's first step toward validation and approval of clinical risk assessment tests for prostate cancer.
PRECISE is led by renowned uro-oncologist and prostate cancer thought leader, Dr. Laurence Klotz, who is chairman of the Canadian Urology Research Consortium, the study sponsor.
Avivagen (TSX-V:VIV) has agreed to supply OxC-beta Livestock to UNAHCO for sales and distribution in the Republic of the Philippines.
OxC-beta has been shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. Comprised of fully-oxidized beta-carotene, OxC-beta is a non-antibiotic means of maintaining optimal health and growth in livestock animals such as swine and poultry.
Microbix Biosystems (TSX:MBX) expects to report revenue in the range of $3.3-million for the fiscal fourth quarter ended Sept. 30, 2016, an increase of 57% from $2.1-million in the year earlier quarter.
Fourth quarter virology revenue is expected to be in the range of $3.3-million, up 106%, compared with $1.6-million in the fourth quarter of fiscal 2015.
Leerink initiated coverage of AC Immune SA (NASDAQ:ACIU) with an “outperform” rating and $22 price target. The stock closed at $14.43 on Friday.
AC Immune is focused on developing novel medicines for neurodegenerative disorders. Its lead asset, crenezumab, which is partnered with Roche/Genentech, is a monoclonal antibody that binds multiple sub-types of beta-amyloid.
Profound Medical (TSX-V:PRN) has entered into an agreement with a syndicate of underwriters, led by GMP Securities, for a bought deal of 15.82 million common shares at a price of $1.10 each for gross proceeds of $17.4-million.
The company has agreed to grant underwriters an overallotment option to purchase up to an additional 2,373,000 common shares at the same price for 30 days following closing. The offering is expected to close on Nov. 14, subject to regulatory approvals.
Titan Pharmaceutical’s (NASDAQ:TTNP) Probuphine six-month implant of sublingual buprenorphine continues to attract widespread media attention for its ability to treat addiction to opioids.
Independent TV station, WHDT, in Stuart, FL. has produced a segment on Probuphine with Dr. Stuart Segal and one of his patients, who was successfully weaned off her use of opioids.
Cormark Securities initiated coverage on BioSyent (TSX-V: RX) with a “buy” recommendation and $10.25 target price. The stock closed at $8.40 on Thursday.
BioSyent establishes and builds out pharmaceutical brands in the Canadian market as well as a growing interest in international jurisdictions. Currently targeting niche products with annual peak revenues of about $20-million each, BioSyent has amassed a portfolio of 11 assets, all of which are growth-stage products or earlier.
Ocular Therapeutix (NASDAQ:OCUL) has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals (NASDAQ:REGN) to develop a sustained release formulation of the vascular endothelial growth factor (VEGF) trap, aflibercept, for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases.
Regeneron’s aflibercept has been approved by the FDA for certain indications under the brand name, EYLEA.
ImmunoVaccine (OTCQX:IMMVF; TSX:IMV) reported positive top-line results from its Phase 1 trial evaluating the safety and immunogenicity of DPX-RSV, its DepoVax-based, small B cell epitope peptide vaccine candidate for respiratory syncytial virus (RSV).
The results six months or more after vaccination confirmed interim data on the ability of DepoVax-formulated antigens to generate a relevant, durable immune response.
Hamilton Thorne (TSX-V:HTL) announced the release of version 1.10 of its world-leading computer assisted sperm analysis (CASA) software.
“As one of the original developers of CASA software and the inventor of the IVOS II, the only fully automated hardware system on the market, we are committed to continual technical innovation,” CEO, David Wolf, said in a statement.